Ask a Librarian

Threre are lots of ways to contact a librarian. Choose what works best for you.

HOURS TODAY

Closed

Reference Desk

CONTACT US BY PHONE

(802) 656-2022

Voice

(802) 503-1703

Text

MAKE AN APPOINTMENT OR EMAIL A QUESTION

Schedule an Appointment

Meet with a librarian or subject specialist for in-depth help.

Email a Librarian

Submit a question for reply by e-mail.

WANT TO TALK TO SOMEONE RIGHT AWAY?

Library Hours for Saturday, April 21st

All of the hours for today can be found below. We look forward to seeing you in the library.
HOURS TODAY
10:00 am - 10:00 pm
MAIN LIBRARY

SEE ALL LIBRARY HOURS
WITHIN BAILEY/HOWE

MapsClosed

Media Services1:00 pm - 5:00 pm

Reference DeskClosed

Cyber Cafe (All Night Study)Closed

OTHER DEPARTMENTS

Special CollectionsClosed

Dana Medical Library9:00 am - 8:00 pm

Classroom Technology ServicesClosed

 

CATQuest

Search the UVM Libraries' collections

UVM Theses and Dissertations

Browse by Department
Format:
Print
Author:
LINTON, ALISHA Anne
Dept./Program:
DEPARTMENT HERE
Year:
2018
Degree:
MS
Abstract:
Background: The 5-hydroxytrptamine receptor 4 (5-HT4 receptor) is heavily expressed on colonic epithelial cells and has been targeted as a therapeutic for functional bowel symptoms and pain; however, adverse cardiac events related to 5-HT4 agonist treatment limited their therapeutic use. Previous studies in the Mawe laboratory have demonstrated that intraluminal application of a 5-HT4 agonist exerts protective epithelial actions in animal models of colitis, and accelerates recovery from colitis. The aim of this study was to test the effects of a luminally restricted 5-HT4 agonist in a mouse model of experimental colitis. Methods: The luminally restricted 5-HT4 agonist (Takeda Pharmaceuticals; 10 mg/kg) was administered to mice during active dextran sodium sulfate (DSS) induced colitis. Colitis activity was evaluated using disease activity index, a fecal lipocalin-2 assay, and histological damage scoring. Epithelial proliferation and colonic motility were also measured as readouts of the potential protective actions and colonic function, respectively. Results: Oral gavage and intracolonic delivery of this luminally restricted 5-HT4 agonist had no detectable effect on recovery from colitis or colonic motility as compared to vehicle. Additionally, in positive control experiments, we failed to see an effect of the 5-HT4 agonist, tegaserod, on colitis severity or colonic motility in any of the measures tested. Conclusions: In conclusion, it is unclear if the luminally restricted 5-HT4 agonist has any effect on recovery from DSS colitis. Given inconsistencies with the model and lack of an effect of tegaserod, additional studies will be required, possibly involving different doses and time points, to fully assess the actions of this luminally restricted compound in colitis recovery.